Abundant neurofibrillary lesions made of the microtubule-associated protein tau constitute a defining neuropathological characteristic of Alzheimer's disease. Filamentous tau protein deposits are also the defining neuropathological characteristic of other neurodegenerative diseases, many of which are frontotemporal dementias or movement disorders, such as Pick's disease, progressive supranuclear palsy and corticobasal degeneration. It is well established that the distribution of tau pathology correlates with the presence of symptoms of disease. However, until recently, there was no genetic evidence linking dysfunction of tau protein to neurodegeneration and dementia. This has now changed with the discovery of close to 20 mutations in the tau gene in frontotemporal dementia with Parkinsonism linked to chromosome 17. All cases with tau mutations examined to date have shown an abundant filamentous tau pathology in brain cells. Pathological heterogeneity is determined to a large extent by the location of mutations in tau. Known mutations are either coding region or intronic mutations located close to the splice-donor site of the intron downstream of exon 10. Most coding region mutations produce a reduced ability of tau to interact with microtubules. Several of these mutations also promote sulphated glycosaminoglycan-induced assembly of tau into filaments. Intronic mutations and some coding region mutations produce increased splicing in of exon 10, resulting in an overexpression of four-repeat tau isoforms. Thus a normal ratio of three-repeat to four-repeat tau isoforms is essential for preventing the development of tau pathology. The new work has shown that dysfunction of tau protein can cause neurodegeneration and dementia.
Introduction
Arnold Pick provided the first clinical description of frontotemporal dementia in 1892 [1] . In 1911, Alois Alzheimer described the neuropathological lesions characteristic of Pick's disease [2] . In the 1960s, these so-called 'Pick bodies' were shown to contain abnormal filaments [3] , which are now known to be made of the hyperphosphorylated, microtubule-associated protein tau [4, 5] . The Pick bodies resemble the neurofibrillary lesions described by Alzheimer in 1907 in the disease subsequently named after him [6, 7] . Filamentous inclusions made of tau protein are also a defining characteristic of other neurodegenerative diseases, such as progressive supranuclear palsy and corticobasal degeneration.
Frontotemporal dementias occur in familial forms and, more commonly, as sporadic diseases. Neuropathologically, they are characterized by a remarkably circumscribed atrophy of the frontal and temporal lobes of the cerebral cortex, often with additional, subcortical changes. In 1994, an autosomal-dominantly inherited familial form of frontotemporal dementia with Parkinsonism was linked to chromosome 17q21.2 [8] . This was followed by the identification of other familial forms of frontotemporal dementia that are linked to this region, resulting in this class of disease being given the denomination frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) [9] . A filamentous inclusion made of hyperphosphorylated tau protein is a major neuropathological characteristic of FTDP-17 [10] . Tau is a microtubule-associated protein that binds to microtubules and promotes microtubule assembly [7] . Tau filaments are space-occupying lesions that may interfere with a host of cellular processes, leading to the degeneration of affected nerve cells and glial cells. Importantly, the tau gene maps to the FTDP-17 locus on chromosome 17. Genetic linkage and neuropathology thus made tau a strong candidate gene for FTDP-17. The discovery of coding-region and intronic mutations in tau has shown that the FTDP-17 locus is indeed the tau gene [11] [12] [13] .
Tau gene mutations
In the adult human brain, six tau isoforms are produced from a single gene by alternative mRNA splicing (Figure 1a , A-F) [14] [15] [16] [17] [18] . They differ from each other by the presence or absence of 29-or 58-amino-acid inserts located in the N-terminal half, and of a 31-amino-acid repeat located in the C-terminal half. Inclusion of the latter, which is encoded by exon 10 of the tau gene, gives rise to three tau isoforms (Figure 1a , D-F) with four repeats each. The other three isoforms (Figure 1a , A-C) have three repeats each. In normal cerebral cortex, similar levels of three-repeat and four-repeat tau isoforms are present. The repeats and some adjoining sequences constitute the microtubule-binding domains of tau [19, 20] .
Tau mutations in FTDP-17 are either missense, deletion or silent mutations in the coding region, or intronic mutations located close to the splicedonor site of the intron downstream of the alternatively spliced exon 10 ( Figure  1 ) [11] [12] [13] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Missense mutations are located in the microtubule-binding repeat region or close to it. Mutations in exon 9 [Gly 272 →Val (G272V)], exon 12 (V337M) and exon 13 (G389R and R406W) affect all six tau isoforms ( Figure  1a ). By contrast, mutations in exon 10 (N279K, ⌬K280, L284L, P301L, P301S, S305N and S305S) only affect tau isoforms with four microtubule-binding repeats or their levels of expression ( Figure 1a ). Most missense mutations reduce the ability of the tau protein to interact with microtubules, as reflected by a reduction in the ability of mutant tau to promote microtubule assembly [23, 30, 38, [41] [42] [43] [44] . Mutations in exon 10 (⌬K280, P301L and P301S) produce the largest effects, with intermediate reductions for mutations in exon 9 (G272V) and exon 12 (V337M), and a smaller reduction for the G389R and R406W mutations in exon 13. Moreover, a number of missense mutations have a direct stimulatory effect on heparin-induced assembly of tau into filaments [45, 46] . This effect is particularly marked for the P301L and P301S mutations, with smaller effects for the G272V and V337M mutations.
Intronic mutations are located in the intron downstream of exon 10 at positions ϩ3, ϩ12, ϩ13, ϩ14 and ϩ16, with the first nucleotide of the splicedonor site taken as ϩ1 (Figure 1b) [12, 13, 25, 26, 34, 39] . Secondary-structure predictions have suggested the presence of an RNA stem-loop structure at the exon 10-intron boundary that is disrupted by the intronic mutations [12, 13] . In addition, the ϩ3 mutation is predicted to lead to increased binding of U1 snRNA to the 5Ј splice site [13] . Exon-trapping experiments have shown that intronic mutations increase splicing-in of exon 10 [12,26,29,32,39,47-49] . Increased production of transcripts encoding exon 10 has also been demonstrated in brain tissue from patients with intronic mutations of tau [12, 39] . This increase is, in turn, reflected in a change in the ratio of three-repeat to fourrepeat tau isoforms, resulting in a net overproduction of four-repeat isoforms [13, 26, 34, 39, 42] . The proposed existence of a stem-loop structure at the boundary between exon 10 and the downstream intron has received support from the determination by NMR spectroscopy of the three-dimensional structure of a 25-nucleotide-long strand of RNA (extending from positions Ϫ5 to ϩ19) ( Figure 1b) [47, 50] . This sequence has been shown to form a stable, folded structure. The stem of the exon 10-splicing regulatory element of tau consists of a single G-C base-pair which is separated from a double helix of six basepairs by an unpaired adenine. The apical loop consists of six nucleotides that adopt multiple conformations in rapid exchange. The structure differs in several respects from the two proposed representations of the stem-loop structure [12, 13] . Known intronic mutations are located in the upper part of the stem of the exon 10-splicing regulatory element of tau ( Figure 1b ). All five mutations reduce the thermodynamic stability of the stem-loop structure, but do so to various extents [39, 47] . The largest drop in melting temperature was observed for the ϩ3 mutation. The ϩ12 and ϩ14 mutations also produced a large reduction in melting temperature, whereas the effects of the ϩ13 and ϩ16 mutations were smaller. The aminoglycoside antibiotic, neomycin, binds to the exon 10-splicing regulatory element of tau and markedly increases the thermodynamic stability of both wild-type and mutated elements [50] . The differential reductions in stem-loop stability resulting from the various intronic FTDP-17 mutations were reflected in the magnitude of increased splicing-in of exon 10, as revealed by exon trapping [12, 29, 39, [47] [48] [49] .
The emerging picture is one of missense mutations which lead to a reduced ability of tau to interact with microtubules and to a stimulatory effect on filament assembly, and of intronic mutations whose primary effects are at the RNA level, resulting in the overproduction of tau isoforms with four microtubule-binding repeats. However, two missense mutations in exon 10 (N279K and S305N) deviate from this rule: they do not lead to a reduction in the ability of tau to promote microtubule assembly [51] . Instead, they increase splicing-in of exon 10, as is the case with the intronic mutations. Mutation N279K (AAT to AAG) creates a purine-rich splice-enhancer sequence, which explains its effects on exon trapping and soluble four-repeat tau in the brain [22] . Similar findings have been obtained with the silent mutation L284L (CTT to CTC) in exon 10, which is believed to disrupt an exon 10-splicing silencer sequence [29] . This work has uncovered the presence of sequence elements within exon 10 that regulate its alternative splicing.
The S305N (AGT to AAT) mutation changes the last amino acid in exon 10 [24] . This sequence forms part of the stem-loop structure, where the muta-tion produces a G to A transition at position Ϫ1 (Figure 1b) . It is, therefore, not surprising that the S305N mutation leads to a reduction in the thermodynamic stability of the stem-loop structure and to a marked increase in the splicing-in of exon 10 [47, 51] . Like the ϩ3 mutation, the Ϫ1 mutation is also expected to lead to increased binding of U1 snRNA to the 5Ј splice site. The silent mutation S305S (AGT to AGC) produces a T to C transition at position 0 that disrupts the stem-loop structure, without a predicted effect on U1 snRNA binding (Figure 1b) [40] . As expected, it produced increased splicingin of exon 10 by exon trapping. Besides mutations in the intron downstream of exon 10, additional pathogenic mutations may exist in other introns of the tau gene. A G to A transition at position ϩ33 of the intron downstream of exon 9 has been described in a patient with familial frontotemporal dementia [23] . It disrupts one of several (A/T)GGG repeats that may play a role in the regulation of the alternative splicing of exon 10.
Neuropathology
All cases with tau gene mutations that have been examined to date have shown the presence of an abundance of filamentous lesions made of hyperphosphorylated tau protein. Strikingly, the morphologies of tau filaments and their isoform compositions appear to be determined by whether tau mutations affect mRNA splicing of exon 10, or whether they are missense mutations located inside or outside exon 10 [52] .
Mutations that affect splicing-in of exon 10 lead to the formation of wide, twisted, ribbon-like filaments that only contain four-repeat tau isoforms. This has been shown in familial multiple system tauopathy with presenile dementia (MSTD) with the ϩ3 intronic mutation [13, 53] , in FTD-Kumamoto with the ϩ12 intronic mutation [39] , as well as in familial progressive subcortical gliosis and Duke family 1684, both with the ϩ16 intronic mutation [26, 34] . Similar results have been obtained in pallido-ponto-nigral degeneration with the N279K mutation in exon 10 whose primary effect is at the RNA level [22, 32, 35] . The same may be true of families with the L284L, S305N and S305S mutations in exon 10 whose primary effects are also at the RNA level. In all these families, the tau pathology is widespread and present in both nerve cells and glial cells, with an abundant glial component.
Mutations in exon 10 that do not affect alternative mRNA splicing lead to the formation of narrow, twisted ribbons that contain four-repeat tau isoforms, with a small amount of the most abundant three-repeat isoform. This has been shown in Dutch family 1 and in an American family, both with the P301L mutation [27, 54] . Based on electron microscopy of tissue sections, the same also appears to be true of the Italian family with the P301S mutation [30] . At present, no neuropathological information is available for patients with the ⌬K280 mutation in exon 10. The P301L, P301S and ⌬K280 mutations all lead to a markedly reduced ability of four-repeat tau to promote microtubule assembly [41] . Exon-trapping experiments have shown that the P301L and P301S mutations have no effect on the splicing-in of exon 10. In contrast, the ⌬K280 mutation leads to reduced splicing-in of exon 10, suggesting that its pri-mary effect might be the overproduction of three-repeat tau, and not the reduced ability of four-repeat tau to interact with microtubules [29] . Clarification of this issue must await the availability of frozen brain tissue from an individual with the ⌬K280 mutation. In brain tissue from individuals with the P301L and P301S mutations, tau pathology is widespread and present in both nerve cells and glial cells; however, when compared with mutations that affect the splicing-in of exon 10, the glial component appears to be less pronounced.
Coding-region mutations located outside exon 10 lead to a tau pathology that is neuronal, without a significant glial component. Some of these mutations lead to the formation of paired helical and straight filaments that contain all six tau isoforms, like the tau filaments of Alzheimer's disease [55] . This has been shown for Seattle family A with the V337M mutation in exon 12 and for a family with the R406W mutation in exon 13 [36, 56] . In both cases, the morphologies of tau filaments have been found to be indistinguishable from those of Alzheimer's disease. By contrast, the G389R mutation in exon 13 produces tau filament morphologies and a pattern of tau bands that resemble the characteristics of Pick's disease [38, 57, 58] . Based on light-microscopic staining, the G272V mutation in exon 9 leads to the formation of numerous Pick-body-like inclusions [54] . These findings indicate that, depending on the positions of missense mutations in exons 9, 12 and 13 of tau, and perhaps the nature of these mutations, a filamentous tau pathology ensues that resembles that of either Alzheimer's disease or Pick's disease.
Pathogenesis
The pathway leading from a mutation in the tau gene to neurodegeneration is unknown. The probable primary effect of most missense mutations is a reduced ability of mutant tau to interact with microtubules (Table 1) . It may be equivalent to a partial loss of function, with resultant microtubule destabilization and deleterious effects on cellular processes, such as rapid axonal transport. However, in the case of the intronic mutations and the N279K, L284L, S305N and S305S mutations in exon 10, this appears unlikely. The net effect of these mutations is increased splicing-in of exon 10, leading to a change in the ratio of three-to four-repeat tau isoforms, and resulting in an overproduction of four-repeat tau. It is well known that four-repeat tau possesses a greater ability to interact with microtubules than three-repeat tau [17] . It is, therefore, possible that, in cases of FTDP-17 with intronic mutations and coding-region Table 1 Proposed sequence of events leading from exonic and intronic mutations in the tau gene to neurodegeneration.
mutations that act at the RNA level, microtubules are more stable than in brain from control individuals. Moreover, missense mutations in exon 10 will only affect 20-25% of tau molecules, with 75-80% of tau being normal.
It is possible, however, that a correct ratio of wild-type three-repeat to four-repeat tau is essential for the normal function of tau in the human brain. An alternative hypothesis is that a partial loss of function of tau is necessary for setting in motion the mechanisms that will ultimately lead to filament assembly. Earlier work has suggested that three-and four-repeat tau isoforms may bind to different sites on microtubules [20] . Overproduction of tau isoforms with four repeats may result in an excess of tau over available binding sites on microtubules, thus creating a gain of toxic function similar to that of most missense mutations, with unbound excess tau available for assembly into filaments (Table 1) .
Where studied, pathological tau from FTDP-17 brain is hyperphosphorylated [7, 10] . Since known mutations in tau do not create additional phosphorylation sites (with the possible exception of the P301S mutation in exon 10), hyperphosphorylation of tau must be an event downstream of the primary effects of the mutation and may be a consequence of the partial loss of function (Table 1) . However, some missense mutations may indirectly affect the phosphorylation state of tau. Thus, in transfected cells, tau protein with the R406W mutation displays only a little phosphorylation at T231, S396 and S404, in contrast with wild-type tau and tau with the P301L or V337M mutation [43, 59] . Hyperphosphorylation of tau probably reinforces the primary effects of the mutations, since it is well established that hyperphosphorylated tau is unable to bind to microtubules and to promote microtubule assembly [60, 61] . At present, there is no experimental evidence linking hyperphosphorylation of tau to filament assembly, and it is unclear whether hyperphosphorylation is either necessary or sufficient for assembly.
Sulphated glycosaminoglycans and RNA induce the bulk assembly of non-phosphorylated, recombinant tau protein into Alzheimer-like filaments in vitro [62] [63] [64] [65] [66] . This work has produced robust methods for the assembly of fulllength tau into filaments. However, the mechanisms that lead to the assembly of tau into filaments in the brain remain to be discovered. It is possible that a reduced ability of tau to interact with microtubules, which could have several different causes, is a necessary step for filament formation (Table 1) . Assembly is an energetically unfavourable, nucleation-dependent process that requires a critical concentration of tau [62, 66] . Many cells may have levels of tau below the critical concentration. Other cells may have effective mechanisms for preventing the formation of tau nuclei, or may be able to degrade them once they have formed.
Insufficient protective mechanisms and high tau concentrations may underlie the selective degeneration of nerve cells and glial cells, which is especially striking in FTDP-17, with the characteristic, sometimes unilateral, razorsharp demarcations between affected and unaffected areas in cerebral cortex. Similar factors may also underpin the late ages of onset of this and other diseases with filamentous tau protein deposits. Protective factors, such as proteases that degrade nucleation products, may be effective throughout much of life. However, as nerve cells age, these mechanisms may become less effective and the balance may shift in favour of filament formation.
The significance of the different filament morphologies observed in FTDP-17 is not clear. It is known that the repeat region of tau forms the densely packed core of paired helical and straight filaments of Alzheimer's disease, with the N-and C-terminal parts of the molecule forming a protease-sensitive coat [55, 67] . Also, for filaments assembled in vitro in the presence of sulphated glycosaminoglycans, the morphology of the filaments depends on the number of repeats in the tau isoform used [62] . Thus, mutations in the repeat region or a change in the relative amounts of three-and four-repeat isoforms could well influence filament morphology. However, treatment of paired helical filaments, which contain all six tau isoforms, with acid leads to untwisted, ribbon-like filaments like those seen in cases of FTDP-17 with mutations in the intron downstream of exon 10, suggesting a close similarity in packing of tau molecules in the various structures [68] . The most important aspect may be the extended filamentous nature of the assemblies and the deleterious effects that this has on intracellular processes, rather than the detailed morphology of the different filaments.
Implications
The discovery of mutations in the tau gene has established that dysfunction of tau protein causes neurodegeneration. Most unexpectedly, it has shown that similar levels of three-and four-repeat tau isoforms are essential for preventing neurodegeneration and dementia.
The finding that overproduction of four-repeat tau leads to its assembly into twisted ribbons and causes disease may shed light on the pathogenesis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), two largely sporadic, neurodegenerative diseases. Neuropathologically they are characterized by an abundant filamentous pathology that is comprised predominantly of four-repeat tau isoforms [69] [70] [71] . A recent study has reported an increase in exon 10-containing transcripts in the brainstem in PSP [72] . It remains to be seen whether this is reflected in increased levels of soluble fourrepeat tau isoforms. An association between PSP and homozygosity of a common allele at a dinucleotide repeat in the intron downstream of exon 9 of the tau gene has been described [73] . More recently, two common tau haplotypes that differ at the nucleotide level, but not at the level of the protein-coding sequence, have been reported [74] . Homozygosity of the more common allele H1 appears to predispose individuals to PSP. Taken together, this work suggests that PSP may be caused by an imbalance between three-and four-repeat tau isoforms, analogous to the FTDP-17 cases with mutations in the intron downstream of tau exon 10. It remains to be seen whether the same is true of CBD. It is noteworthy that a patient with the S305S mutation in tau presented with the symptoms of PSP [40] , whereas a patient with the P301S mutation in tau showed the clinical signs of CBD [30] .
The discovery that some mutations in tau exons 9 and 13 give rise to a clinical picture and a neuropathology similar to those of Pick's disease, indi-cates their relevance for an understanding of the aetiology and pathogenesis of Pick's disease. These mutations affect all six tau isoforms, and in cases with the G389R mutation in exon 13, the tau filaments contain three-and four-repeat isoforms [38] . This is in apparent contrast to sporadic Pick's disease, which is characterized by the assembly of three-repeat, but not four-repeat, tau into filaments [75, 76] .
All cases of FTDP-17 examined to date are characterized by an abundant filamentous tau pathology. The V337M and R406W mutations lead to a tau pathology that is identical to that of Alzheimer's disease in its biochemical and morphological characteristics [36, 56] . It follows that in Alzheimer's disease nerve cells may also degenerate as a direct result of the development of tau filaments. Unlike in Alzheimer's disease, abundant neuritic plaques are not a general characteristic of FTDP-17; however, isolated cases of FTDP-17 with abundant amyloid deposits have been described [29, 36] . Although one cannot exclude associated Alzheimer's disease pathology in these patients, future work may uncover mechanisms by which the development of tau pathology can lead to deposition of ␤-amyloid.
Prevention or reduction of tau pathology is likely to be beneficial therapeutically. Current evidence suggests that binding of tau to microtubules and self-assembly of tau into filaments are mutually exclusive. Therefore, increasing the ability of abnormally hyperphosphorylated tau to interact with microtubules may be of benefit. This could, in principle, be achieved by using specific protein kinase inhibitors, proteins that bind to protein kinases and inactivate them or a cis-trans prolyl isomerase, such as Pin1 [77] [78] [79] . The latter has been shown to bind to hyperphosphorylated tau protein in vitro and restore its ability to interact with microtubules [79] . Naturally occurring osmolytes, such as trimethylamine N-oxide, have also been shown to restore the ability of phosphorylated tau to interact with microtubules [80] . Assembly of tau into filaments is a nucleation-dependent process that is strongly concentration dependent. Therefore, a reduction in the cellular levels of tau protein must be a therapeutic target. This is especially true of tau mutations whose primary effect is at the RNA level. Small organic compounds that specifically stabilize the stem-loop structure at the boundary between tau exon 10 and the intron downstream of exon 10 may be able to restore the disturbed ratio between three-and four-repeat tau isoforms [50] . Compounds that prevent the assembly of tau protein into filaments can be identified using existing methods for filament formation in vitro. Validation of their usefulness will require the development of experimental animal models of tau filament formation. Although current transgenic mouse models have exhibited some signs of neurodegeneration as a result of the overexpression of human tau protein, they have so far failed to show abundant tau filaments [81] [82] [83] [84] [85] . The hope is that expression of mutant human tau isoforms in transgenic mice will result in the formation of tau filaments in nerve cells and glial cells. This is not only important for the study of FTDP-17, but also constitutes a necessary prerequisite for a true animal model of Alzheimer's disease.
